Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Fig. 2

Illustration of potential synergistic effects of SGLT2 inhibitor with ACEI/ARB in DKD therapy. ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, SGLT2i Sodium–glucose co-transporter 2 inhibitor, RAAS renin–angiotensin–aldosterone system, UGE urinary glucose excretion, BP blood pressure, SBP systolic blood pressure, HDL-C high density lipoprotein-cholesterol, eGFR estimated glomerular filtration rate, DKD diabetic kidney disease

Back to article page